Job Trends
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
THE LATEST
Blocking IL-6 pathway may extend duration of immunotherapy and reduce side effects
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Research Team Combines Multi-Spectral Imaging and Supercomputing
Florida-based Hesperos is changing the paradigm of clinical development with its organ-on-a-chip technology and new research that demonstrates the platform can predict in vivo response to medications and reduce the need for animal testing.
Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Median progression-free survival for patients receiving Braftovi Triplet was 4.3 months compared to 1.5 months.
Process Could Be Similar to How First Living Cells Formed; Applications to Industry Possible
Biotech and pharma companies strengthen their executive leadership and board positions.